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ABSTRACT
Rationale: There is limited knowledge on the effect of acute exacerbations in chronic obstructive 
pulmonary disease (AECOPD) on lung cancer risk in COPD patients with and without a history of 
asthma. This study aims to examine whether AECOPD is associated with risk of lung cancer, and 
whether the effect depends on a history of asthma.
Methods: In the GenKOLS study of 2003–2005, 852 subjects with COPD performed spirometry, 
and filled out questionnaires on smoking habits, symptoms and disease history. These data were 
linked to lung cancer data from the Cancer Registry of Norway through 2013. AECOPD, measured 
at baseline was the main predictor. To quantify differences in lung cancer risk, we performed Cox- 
proportional hazards regression. We adjusted for sex, age, smoking variables, body mass index, 
and lung function.
Measurements and results: During follow-up, 8.8% of the subjects with, and 5.9% of the 
subjects without exacerbations were diagnosed with lung cancer. Cox regression showed 
a significant increased risk of lung cancer with one or more exacerbations in COPD patients 
without a history of asthma, HRR = 2.77 (95% CI 1.39–5.52). We found a significant interaction 
between a history of asthma and AECOPD on lung cancer.
Conclusions: AECOPD is associated with an increased risk of lung cancer in COPD patients 
without a history of asthma.
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Introduction
Compared to healthy smokers, smokers suffering from 
COPD have an increased risk of lung cancer [1]. 
Emphysema [2] and airway obstruction [1] increase 
the risk of lung cancer, but there is limited knowledge 
on how other features of COPD, such as acute exacer-
bations in COPD (AECOPD) affect lung cancer 
incidence.
Chronic inflammation is central to the development 
of COPD [3]. Inflammation is further thought to play 
an essential part in the pathogenesis of lung cancer in 
COPD patients [4]. Since both local and systemic 
chronic inflammation is a characteristic of COPD 
exacerbations [5–7], one might hypothesize that acute 
exacerbations in COPD increase the risk of lung 
cancer.
Few studies have examined AECOPD and the risk 
for lung cancer, and these studies show conflicting 
results [7,8]. In a nested case–control study from the 
COPDGene cohort, patients with COPD with incident 
lung cancer reported a higher frequency of exacerba-
tions 12 months prior to study enrolment [8]. In 
another study, including 433 COPD patients and 279 
healthy controls, AECOPD was not related to the 
increased incidence of lung cancer during 9 years of 
follow-up [7].
Patients with a history of asthma have often been 
excluded from COPD studies. This was also the case 
with the study of Husebø et al. [7]. COPD patients with 
a history of asthma may have a different exacerbation 
phenotype compared to COPD patients without 
a history of asthma [9]. Hence, the risk of lung cancer 
from AECOPD might vary by a history of asthma [10].
We had access to a population-based cohort of sub-
jects with COPD, which included information regard-
ing asthma diagnosis as well as AECOPD the year 
before inclusion. This information was linked to data 
from the Cancer Registry of Norway [11] in order to 1) 
explore whether AECOPD was associated with an 
increased risk of lung cancer during 10-year follow- 
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up, and 2) whether the risk of lung cancer due to 
AECOPD differed based on a history of asthma.
Materials and methods
Prior to enrolment, information was given and written 
informed consent obtained from all study subjects. The 
study was reviewed and approved by the Western 
Norway Regional Committee for Medical and Health 
Research Ethics, reference number 2010/2575/REK vest.
Study population
The subjects in the current analyses were all participants in 
the GenKOLS study (Genetic COPD study) conducted 
between January 2003 and January 2005 in Bergen, 
Norway. Details on the GenKOLS population are pre-
sented elsewhere [12]. GenKOLS was a case–control 
study, and the subjects in the current analyses comprised 
the COPD cases only. Participants were 40–85 years of age 
and had a smoking history of at least 2.5 pack-years at 
baseline. COPD was diagnosed when post-bronchodilator 
FEV1/FVC was <0.70 and FEV1 < 80% predicted. Baseline 
examinations included a detailed questionnaire on smok-
ing habits, respiratory symptoms, and disease history, as 
well as pulmonary function tests. We also obtained inci-
dence data from the Cancer Registry of Norway [11] 
throughout the year 2013. All subjects with a cancer diag-
nosis before inclusion were excluded from the analyses. 
Due to missing information on emigration date, also four 
individuals that emigrated during follow-up were excluded.
Main variables
Lung cancer incidence was the primary outcome vari-
able. We retrieved information on the study partici-
pants who developed lung cancer from January 2003 
through December 2013 from the Cancer Registry of 
Norway, which contains data on all individuals in 
Norway diagnosed with cancer [11]. Registration is 
regulated by law, and registration of patients is man-
datory both for pathologists and clinical doctors, with 
a near 100% completeness [13]. Lung cancer was iden-
tified in the registry by the ICD-10-code C34. The data 
from the Cancer Registry included time of diagnosis 
and histologic classification of the cancer.
Acute exacerbations of COPD (AECOPD) was the 
main predictor of interest. AECOPD was defined as 
events where courses of antibiotics were administered 
due to lung disease in the last 12 months preceding 
inclusion. The question asked was, ‘Have you had 
treatment with antibiotics for lung disease during the 
last 12 months?’ and “If YES, how many times?
Participants were considered to have a history of 
asthma if they gave affirmative answers to both: ‘Have 
you had asthma?’ and ‘if yes, was this confirmed by 
a doctor?’
Other variables
Smoking status was defined as the current status at inclu-
sion. Pack-years of tobacco smoking was defined as 
(number of cigarettes smoked per day/20) x number of 
years smoked. We also recorded age at onset of smoking. 
Educational level, height, weight, and pulmonary func-
tion tests were measured at inclusion [14]. Spirometries 
were performed according to the American Thoracic 
Society standards [15]. Local reference values for FEV1 
and FVC were used [16]. The date of death was obtained 
by linkage to the Norwegian National Cause of Death 
Registry [17]. Patients were followed until a diagnosis 
with lung cancer, date of death, or end of follow-up in 
December 2013, whichever came first.
Statistical analyses
Since only eight individuals developed lung cancer in the 
group with two or more exacerbations in the 
preceding year, AECOPD was analysed as 
a dichotomous variable (0 vs. 1 or more exacerbations). 
The Kaplan-Meier method was used to calculate and plot 
probabilities for developing lung cancer. To quantify 
differences in the risk of developing lung cancer, we 
performed Cox-proportional hazards regression and 
reported hazard rate ratios (HRR) [18]. Covariates in 
the adjusted analyses were sex, age, pack-years, age of 
onset of smoking, smoking status at inclusion, body mass 
index (BMI), and FEV1. The interaction between 
AECOPD and a history of asthma on lung cancer was 
also tested.
Furthermore, analyses stratified by a history of 
asthma were presented. To take mortality into account, 
as a competing risk, we also performed Fine and Gray 
competing risk analyses for the probability of develop-
ing cancer. The results from the Fine and Gray model 
[19], presented as sub-hazard rate ratios (SHRR), are 
presented in the online supplement.
All analyses were performed using STATA version 
16. (StataCorp. TX, USA). A two-sided significance 
level of 0.05 was applied for all analyses.
Results
Altogether, there were 852 COPD patients included in 
the study, of which 38.4% were women. The mean age 
was 65.1 (SD = 10.1) years, 30.5% had one or more 
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exacerbation during the last 12 months before inclu-
sion, and 49.5% reported a history of asthma at inclu-
sion. COPD patients with a history of asthma 
comprised more women, had a lower smoking con-
sumption in terms of pack-years, had more exacerba-
tions 12 months prior to inclusion, and a lower lung 
function in terms of FEV1 in percent predicted than 
COPD patients without a history of asthma (Table 1).
For the entire sample, 8.8% of the COPD patients 
with and 5.9% of the COPD patients without exacer-
bations were diagnosed with lung cancer. Average time 
from inclusion to lung cancer diagnosis was 4.5 years 
(range: 43 days to 10.4 years), and did not differ sig-
nificantly between those with and without exacerba-
tions. For the COPD patients without a history of 
asthma, and at least one exacerbation 12 months before 
inclusion 14 individuals, 14.0%, got a lung cancer diag-
nosis, whereas 9 individuals, 5.6%, got lung cancer in 
the group of patients with a history of asthma, and at 
least one exacerbation 12 months prior to inclusion.
In unadjusted Cox-regression analyses on the entire 
sample, increasing age and decreasing BMI were sig-
nificantly associated with the risk of lung cancer, the 
HRR being 1.03 (95% CI 1.00–1.06) per year, and 
HRR = 0.93 (95% CI 0.88–0.99) per kg/m2, respec-
tively. Exacerbation status at inclusion was also related 
to the risk of lung cancer (borderline non-significant). 
The HRR for lung cancer in those with one or more 
exacerbations as compared to no exacerbations 
12 months before inclusion was 1.58 (95% CI 
0.93–2.67).
In COPD patients without a history of asthma, those 
with one or more exacerbations had a higher probabil-
ity of lung cancer than those without exacerbations 
(Figure 1(a)), while for COPD patients with a history 
of asthma, the probability of lung cancer did not differ 
between those with and without exacerbations (Figure 
1(b)).
For COPD patients without a history of asthma, we 
found that those with exacerbations had an HRR for 
lung cancer of 2.77 (95% CI 1.39–5.52) compared to 
those without exacerbations. For COPD patients with 
a history of asthma, the corresponding number was 
0.90 (95% CI 0.40–2.05) (Table 2). When adjusting 
for sex, age, smoking status and consumption, FEV1, 
and BMI at inclusion, the risk ratio for lung cancer in 
those with exacerbations (compared to those without) 
remained significantly increased in the non-asthma 
group and was still insignificant in those with 
a history of asthma (Figure 2).
Adding an interaction term between a history of 
asthma and exacerbation status in the adjusted Cox- 
regression analysis on the entire sample, we found that 
the interaction term reached a level of significance. 
This shows that there is an additional effect of exacer-
bations for patients without a history of asthma (Table 
E1, online supplement).
Table 1. Baseline characteristics by a history of asthma.
No asthma Asthma P-value
Subjects, n 430 422
Sex, female (%) 30.5 46.5 <0.001
Years of age, mean (SD) 64.9 (10.2) 65.4 (10.0) 0.528
Current smokers (%) 47.0 45.3 0.615







Age of onset of smoking, mean (SD) 18.4 (4.5) 18.9 (5.8) 0.098
~AECOPD, mean (SD) 0.3 (0.8) 0.8 (1.5) <0.001
Lung cancer (%) 7.7 5.9 0.311





^PB FEV1 pp, mean (SD) 54.6 (17.3) 47.0 (17.0) <0.001
~ Acute exacerbations in COPD, §Body mass index, ^Post-bronchodilator 
FEV1% predicted. 
Figure 1. Free of cancer estimates for lung cancer by AECOPD in COPD patients without (a) and with a history asthma (b).
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The Fine and Gray competing risk model for the 
probability of developing lung cancer, taking patient 
mortality into account, gave virtually the same results 
as the Cox-regression analysis. Results are presented in 
the online supplement (Table E2).
The histological subtypes of lung cancer comprised 
33.9% adenocarcinoma, 22.0% squamous cell, 10.2% 
small cell lung cancer, 25.4% unspecified non-small 
cell lung cancer, and 8.5% had unknown histology 
type. No relationship between AECOPD and histologi-
cal subtypes was found (data not shown).
Discussion
The main finding of this study on subjects with COPD 
followed for 10 years was that AECOPD was only 
significantly associated with an increased risk of lung 
cancer in COPD patients without a history of asthma. 
The association was independent of sex, age, BMI, lung 
function, pack-years, age of onset of smoking, and 
smoking status at baseline.
Our findings are in line with Carr et al. in show-
ing an association between AECOPD and lung can-
cer risk [8]. In the study by Carr et al., they saw an 
effect on lung cancer incidence already after 1 year 
of follow-up, whereas we saw it after 5 years 
(Figure 1). A potential explanation for this difference 
is that Carr et al. followed a cohort of subjects with 
and without COPD, whereas we had COPD patients 
only. They also had a case–control study design 
comparing lung cancer cases to non-lung cancer 
cases. When exploring the association between 
AECOPD and lung cancer in COPD cases only, 
they were not able to produce significant results. 
They followed their cohort for an average of 
5.7 years, of which 24% had <5 years follow-up, 
and 10% of their subjects had no follow-up. Hence, 
they expected some lung cancers to be unreported 
and did not know their survival outcomes [8]. In the 
present study, we had 10 years of follow-up and 
access to the Cancer Registry of Norway with practi-
cally 100% coverage. Another study looking at sev-
eral risk factors for lung cancer in COPD found no 
association between AECOPD and risk of lung can-
cer [7]. They detected 32 lung cancer cases and did 
Table 2. Unadjusted Cox-regression analyses. The risk for lung 
cancer in COPD patients with and without a history of asthma.
No asthma Asthma
‘HRR 95% CI ‘HRR 95% CI
Sex 1.72 0.75–3.97 0.83 0.38–1.82
Age 1.03 0.99–1.07 1.02 0.98–1.07
Pack Years 1.01 0.99–1.03 1.01 0.99–1.03
Current smokers 0.71 0.35–1.41 0.84 0.38–1.86
Age of onset of smoking 0.96 0.88–1.05 1.02 0.95–1.08
^PB FEV1 pp 0.83 0.69–1.01 0.91 0.72–1.16
§BMI (kg/m^2) 0.91* 0.84–0.98 0.96 0.88–1.04
Education 0.70 0.40–1.23 0.62 0.31–1.21
~AECOPD, 1 or more 2.77** 1.39–5.52 0.90 0.40–2.05
‘Hazard Rate Ratio, ^Post-bronchodilator FEV1% predicted, divided by 10. 
§Body mass index, ~Acute exacerbations in COPD, * p < 0.05, ** p < 0.01. 
Figure 2. Unadjusted and adjusted Cox-regression analyses. Risk for lung cancer in COPD patients without and with a history of 
asthma.
Adjusted for sex, age, pack-years, age of onset of smoking, smoking status, BMI, and FEV1. 
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not report the number of exacerbations. The lack of 
an association in their study could be due to small 
numbers and low statistical power.
We observed a significant association between 
AECOPD and lung cancer risk only in COPD patients 
without a history of asthma. To our knowledge, this is 
the first study to explore whether there is a difference 
between the effect of AECOPD on lung cancer in 
COPD patients based on a history of asthma.
This finding could have several explanations. First, 
one recent retrospective study found that coexisting 
asthma in COPD patients was associated with 
decreased risk of lung cancer [10]. This could indicate 
that COPD patients with a history of asthma represent 
a phenotype caused by different mechanisms, and 
therefore, a reduced risk of lung cancer. Their study 
did, however, have several weaknesses. COPD was 
defined without spirometry, and they were not able 
to adjust for lung function in the statistical analyses. 
They also lacked information on tobacco exposure, 
which might explain lower lung cancer risk for those 
with asthma. Second, several studies have found 
a decreased risk of lung cancer with inhaled steroids 
[7,20–22]. This could be due to reduced airway 
inflammation, and that decreased cell turnover lowers 
the risk for the propagation of genetic errors [20]. 
Patients with a history of asthma might have used 
more inhaled steroids, and COPD patients with clin-
ical features similar to asthma are found to respond 
better to corticosteroids than COPD patients without 
[23]. However, the same effect of ICS on lung cancer 
has not been seen in randomized controlled trials 
[24,25]. On the other hand, randomized controlled 
trials might not have sufficient follow-up time or the 
proper design to examine the effect on lung cancer 
risk by ICS. Hence, a possible protective effect of ICS 
on lung cancer might still be present, but unproven 
[26,27]. Third, inflammation is an essential part of the 
pathogenesis in lung cancer development in patients 
suffering from COPD [4]. COPD is considered 
a systemic disease [28] in which the frequent exacer-
bations phenotype is associated with increased sys-
temic inflammation [7]. AECOPD have different 
triggers, clinical manifestations, biomarkers, comor-
bidities, and exacerbation frequencies [9]. 
Neutrophilic inflammation driven by CD8 + T-cells 
are often seen in COPD, whereas inflammation in 
asthma patients more often is eosinophilic and 
mediated by CD4 + T-cells [29]. One might hypothe-
size that the neutrophilic inflammation increases lung 
cancer risk more than the eosinophilic. Fourth, trig-
gers such as viruses and bacteria are thought to cause 
most exacerbations [30,31]. Some bacteria and more 
viruses play an essential part in cancer development of 
other types of cancer [32,33]. It could be that some 
bacteria or viruses lead to cancer development also in 
the lungs. We do not know whether different COPD 
phenotypes have different triggers to AECOPD. Fifth, 
tobacco exposure is a prevalent risk factor for both 
lung cancer and COPD. COPD patients with a history 
of asthma smoked less than COPD patients without 
a history of asthma (Table 1). It could be that the 
chronic inflammation and enzymatic imbalance 
caused by tobacco is less present in asthma patients. 
Also, other possible confounders should be consid-
ered. The group without a history of asthma had 
higher educational level than the group with 
a history of asthma, implying no beneficial effect on 
lung cancer risk from education (Table 1). We 
adjusted for pack-years, age of onset of smoking, 
smoking status, age, sex, and lung function in the 
adjusted analyses, but residual confounding cannot 
be ruled out.
For the statistical analyses in this article, we used 
Cox-proportional hazards regression. Using the 
increasingly popular Fine and Gray competing risk 
regression, taking patient mortality into account, we 
found virtually the same as using Cox-regressions 
(Table E2). Still, one could argue that competing risk 
models are better suited for studying the clinical prog-
nosis of the patient since the risk for the patient dying 
is accounted for [18].
There are several strengths in this study. First, it is 
a sizeable single-centre study that allows for extensive 
adjustment for relevant confounders. Second, partici-
pants were not sampled from a cancer screening trial, 
but a community-based sample followed for more 
than 8000 person-years. Third, it is a prospective 
study in which all lung cancers were incident cases 
diagnosed after baseline measures of exacerbations. 
Fourth, cancer diagnosis was taken from the Cancer 
Registry of Norway, which has close to a 100% inclu-
sion rate and provide histology verified diagnosis [13]. 
Fifth, spirometry was performed by all participants, 
and chronic airway obstruction verified in all subjects 
with COPD.
The present study also has some limitations. First, 
the GenKOLS study was initially designed as a case- 
control study to examine subjects with COPD. We, 
therefore, have few cancer cases compared to those 
sampled in screening trials. Due to small numbers of 
lung cancer, the lack of association between AECOPD 
and histological subgroups of lung cancer should be 
interpreted with care. Second, moderate to severe 
AECOPD is usually treated with either antibiotics, sys-
temic steroids, or both, based on clinical manifestation. 
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In our study, we only had data on events that were 
treated with antibiotics. Therefore, we do not know if 
there were any events that needed steroid treatment. 
The numbers of exacerbations were, however, similar 
to the numbers presented by the comparable 
GeneCOPD study [8]. Furthermore, some of the events 
that had been treated with antibiotics could have been 
a pneumonia and not an exacerbation. Previous pneu-
monia is found to predict lung cancer [34] and cannot 
be ruled out as a potential source of bias. Third, the 
asthma diagnosis was questionnaire-based and pre-
sented a history of asthma as opposed to a current 
clinical diagnosis. It might be that some of the subjects 
received a wrong diagnosis earlier in life. The charac-
teristics of COPD patients with a history of asthma 
were in line with another study in seeing a smaller 
amount of tobacco consumption, lower FEV1, and 
higher exacerbation frequency, compared to COPD 
patients without a history of asthma [35]. The preva-
lence of asthma in this population of subjects with 
COPD is in line with other epidemiological studies 
[36–39], but higher than in clinical trials [40,41]. 
A misclassification of asthma is likely to be non- 
differential when comparing those with and without 
cancer, due to a prospective study design where both 
participants and the study crew were unaware of the 
future lung cancer diagnosis at the time of inclusion. 
Fourth, never-smokers were not included in the study, 
which prevented us from generalizing the findings to 
a never-smoking population. We did, however, include 
tobacco consumption down to 2.5 pack-years. Fifth, we 
did not include GOLD stage I, which in some studies 
have shown to have the highest incidence of lung 
cancer [42]. Sixth, we used a fixed ratio for COPD 
diagnosis, which might lead to over-diagnosis in elderly 
subjects when compared to the lower limit of normal.
Clinical relevance
We know that COPD is a risk factor for lung cancer 
[43]. Nevertheless, most randomized control trials 
have had recruitment criteria based on age and smok-
ing history alone [44–49]. This study suggests that 
AECOPD and asthmatic features of COPD should be 
considered when evaluating those at higher risk. More 
studies, including validated information on acute 
exacerbations in COPD patients with and without 
a history of asthma, are needed to better understand 
which mechanisms link COPD and lung cancer. As 
we learn more about the clinical phenotypes of 
COPD, one can easier target COPD patients at higher 
risk of lung cancer and determine who to include in 
screening trials.
Conclusion
Acute exacerbations of COPD are associated with an 
increased risk of lung cancer in those without a history 
of asthma, but not in those with a history of asthma.
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